122332-18-7

Usage

Uses

Antineoplastic (microtubule inhibitor).

InChI:InChI=1/C17H19N5O2/c1-3-24-17(23)21-13-9-12-15(16(18)20-13)22-14(10(2)19-12)11-7-5-4-6-8-11/h4-10,19H,3H2,1-2H3,(H3,18,20,21,23)/t10-/m0/s1

Upstream product

• 122293-99-6 ethyl (S)-6-amino-4-<(1-methyl-2-oxo-2-phenylethyl)-amino>-5-nitropyridine-2-carbamate 
• 492-41-1 (1R,2S)-norephedrine 
• 6506-86-1 ethyl (6-amino-4-chloro-5-nitropyridin-2-yl)carbamate 
• 122293-97-4 ethyl -6-amino-4-<(2-hydroxy-1-methyl-2-phenylethyl)amino>-5-nitropyridine-2-carbamate 

Relevant academic research and scientific papers

New Anticancer Agents: Chiral Isomers of Ethyl 5-Amino-1,2-dihydro-2-methyl-3-phenylpyridopyrazine-7-carbamate

Racemic ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyridopyrazine-7-carbamate (1a) has shown antitumor activity in a variety of in vivo experiments.The preparation of the R (9) and S (10) isomers gave compounds with significant differences in potency in several biological tests.

'(2S)-(5-amino-1,2-dihydro-2-methyl-3-phenylpyrido(3,4-b)pyrazin-7-yl)-carbamic acid, ethyl ester

The (2S)-(-)-isomer of (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)arbamic acid, ethyl ester is significantly more potent than either the (2R)-(+)-isomer or the (R,S)-(±)- racemic mixture in inhibiting mitotic cell division of L1210 leukemia cells. The compound, pharmaceutical compositions containing the compound, and a method of ameliorating cancer diseases in mammals are disclosed.